BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28265008)

  • 21. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma.
    Poth KJ; Guminski AD; Thomas GP; Leo PJ; Jabbar IA; Saunders NA
    Mol Cancer Ther; 2010 Aug; 9(8):2430-9. PubMed ID: 20682658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of WD repeat domain 5 associates with aggressive clinicopathological features and unfavorable prognosis in head neck squamous cell carcinoma.
    Wu Y; Diao P; Li Z; Zhang W; Wang D; Wang Y; Cheng J
    J Oral Pathol Med; 2018 May; 47(5):502-510. PubMed ID: 29569374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
    Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
    Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
    Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
    J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
    Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
    Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
    Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
    Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
    Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
    Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
    Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
    Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
    Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
    Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
    J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
    Lopes-Coelho F; Gouveia-Fernandes S; Gonçalves LG; Nunes C; Faustino I; Silva F; Félix A; Pereira SA; Serpa J
    Tumour Biol; 2016 Apr; 37(4):4813-29. PubMed ID: 26520442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
    Ren A; Qiu Y; Cui H; Fu G
    Biochem Biophys Res Commun; 2015 Mar; 459(1):10-7. PubMed ID: 25634693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma.
    Muhammad N; Bhattacharya S; Steele R; Phillips N; Ray RB
    Clin Cancer Res; 2017 Jun; 23(12):3120-3128. PubMed ID: 27965308
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.
    Kothari V; Mulherkar R
    Anticancer Res; 2012 Jan; 32(1):121-8. PubMed ID: 22213296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
    Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
    Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial-mesenchymal transition and cancer stem cells: A route to acquired cisplatin resistance through epigenetics in HNSCC.
    Lima de Oliveira J; Moré Milan T; Longo Bighetti-Trevisan R; Fernandes RR; Machado Leopoldino A; Oliveira de Almeida L
    Oral Dis; 2023 Jul; 29(5):1991-2005. PubMed ID: 35403781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
    Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
    Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.